Page last updated: 2024-08-26

bosentan anhydrous and Substance Withdrawal Syndrome

bosentan anhydrous has been researched along with Substance Withdrawal Syndrome in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Frost, AE; Suleman, N1
Behrends, M; Beiderlinden, M; Peters, J1

Other Studies

2 other study(ies) available for bosentan anhydrous and Substance Withdrawal Syndrome

ArticleYear
Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
    Chest, 2004, Volume: 126, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Long-Term Care; Male; Middle Aged; Substance Withdrawal Syndrome; Sulfonamides; Treatment Outcome

2004
Combination of sildenafil and bosentan for nitric oxide withdrawal.
    European journal of anaesthesiology, 2005, Volume: 22, Issue:2

    Topics: Antihypertensive Agents; Bosentan; Extracorporeal Membrane Oxygenation; Female; Humans; Middle Aged; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Respiratory Distress Syndrome; Sildenafil Citrate; Substance Withdrawal Syndrome; Sulfonamides; Sulfones; Vasodilator Agents; Ventilator Weaning

2005